Minck D R, Acuff-Smith K D, Vorhees C V
Institute for Developmental Research, Children's Hospital Research Foundation, Cincinnati, Ohio 45229.
Teratology. 1991 Apr;43(4):279-93. doi: 10.1002/tera.1420430402.
Pregnant Sprague-Dawley CD rats were orally administered either phenytoin (PHT, 200 mg/kg), mephenytoin (MPH, 100 mg/kg), ethotoin (ETH, 600 mg/kg), hydantoin (HYD, 1,200 mg/kg) or vehicle (propylene glycol) on days 7-18 of gestation. Mean (+/- S.E.) maternal serum concentrations of PHT, MPH, and ETH 1 hour after dosing on gestational day 18 were 16.0 +/- 3.3, 10.7 +/- 3.0, and 65.2 +/- 10.45, respectively, and free fractions were 16%, 18%, and 11% respectively. The free fraction for PHT is similar, but was lower for both MPH and ETH than that seen in humans. Preweaning mortality for PHT, MPH, ETH, HYD, and controls was 25%, 6.3%, 12.5%, 2.0% and 0.8%, respectively. The MPH and ETH-exposed animals weighed approximately 6.6% less than controls throughout the study; the other groups did not differ significantly. PHT offspring showed increased early locomotor activity. Only PHT-exposed animals (27%) exhibited abnormal circling behavior after weaning. PHT-circlers accounted for higher levels of activity in an open-field test and for longer straight channel swimming times. PHT-circlers and noncirclers differed from one another and controls on performance of a complex (Cincinnati) maze and on the development of the air-righting reflex. Offspring prenatally exposed to MPH showed an early delay in air-righting. ETH and HYD offspring were not consistently different from controls in behavior. The data suggest the following ordinal relationship among the drugs for behavioral teratogenesis: PHT much greater than MPH greater than ETH congruent to HYD congruent to CON. The effects of PHT are consistent with previous findings. Data on the other drugs suggest that other hydantoins do not possess the behavioral teratogenic efficacy of PHT and that PHT may be unique in its effects on CNS development.
在妊娠第7至18天,给怀孕的斯普拉格-道利CD大鼠口服苯妥英(PHT,200毫克/千克)、美芬妥英(MPH,100毫克/千克)、乙苯妥英(ETH,600毫克/千克)、海因(HYD,1200毫克/千克)或赋形剂(丙二醇)。妊娠第18天给药后1小时,母体血清中PHT、MPH和ETH的平均(±标准误)浓度分别为16.0±3.3、10.7±3.0和65.2±10.45,游离分数分别为16%、18%和11%。PHT的游离分数相似,但MPH和ETH的游离分数均低于人类。PHT、MPH、ETH、HYD组及对照组的断奶前死亡率分别为25%、6.3%、12.5%、2.0%和0.8%。在整个研究过程中,暴露于MPH和ETH的动物体重比对照组轻约6.6%;其他组无显著差异。PHT组后代早期运动活动增加。只有暴露于PHT的动物(27%)在断奶后表现出异常的转圈行为。PHT组转圈动物在旷场试验中的活动水平较高,在直通道游泳时间较长。PHT组转圈动物和非转圈动物在复杂(辛辛那提)迷宫表现和空中翻正反射发育方面与对照组不同。产前暴露于MPH的后代在空中翻正方面出现早期延迟。ETH和HYD组后代在行为上与对照组无一致差异。数据表明这些药物在行为致畸方面存在以下顺序关系:PHT远大于MPH大于ETH等同于HYD等同于对照组。PHT的作用与先前的研究结果一致。其他药物的数据表明,其他海因类药物不具有PHT的行为致畸效力,且PHT对中枢神经系统发育的影响可能是独特的。